Nexalin Technology Inc (NXL) Stock Price, Quote & News

Company Profile

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health epidemic in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic br...

Industry: Medical Devices

Sector: Healthcare

Phone: 832 260 0222

Website: www.nexalin.com

Address:

1776 Yorktown, Suite 550, Houston, United States

MrTicker Jun. 4 at 3:31 PM

$NXL Nexalin Technology Wins US Patent Protecting Neurostimulation Method Through 2042 MT NEWSWIRES 10:26 AM ET 6/4/2026

0 · Reply

focafoca99 Jun. 4 at 3:02 PM

$NXL secures a U.S. patent for dynamic frequency stimulation covering anxiety, depression, and insomnia through 2042.

0 · Reply

MrTicker Jun. 4 at 2:03 PM

$NXL Newly issued U.S. patent expected to provide core intellectual property protection through 2042, further strengthening Nexalin’s proprietary position in non-invasive frequency-based deep-brain neurostimulation Patent covers transcranial alternating current dynamic frequency stimulation methods for anxiety, depression and insomnia — three large and underserved markets central to Nexalin’s HALO™ Clarity and NeuroCare™ strategies

0 · Reply

MrTicker Jun. 4 at 2:03 PM

$NXL Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia GLOBENEWSWIRE 9:00 AM ET 6/4/2026

0 · Reply

MaskMaker Jun. 4 at 5:49 AM

$NXL $UNH $VTGN $JNJ

0 · Reply

MaskMaker Jun. 4 at 5:45 AM

$NXL

0 · Reply

MaskMaker Jun. 3 at 8:33 PM

$NXL $VTGN $GRRR

1 · Reply

MaskMaker Jun. 3 at 4:00 PM

$NXL

0 · Reply

MaskMaker Jun. 2 at 6:43 AM

$NXL

0 · Reply

Nousernam3 Jun. 2 at 1:04 AM

$NXL

0 · Reply

Nexalin Technology announces issuance of new U.S. patent

Jun 4, 2026, 10:00 AM EDT - 12 hours ago

Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia

May 21, 2026, 8:30 AM EDT - 14 days ago

Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury

May 19, 2026, 8:30 AM EDT - 16 days ago

Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial

Apr 28, 2026, 9:15 AM EDT - 5 weeks ago

Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia

2026-04-22T14:03:36.000Z - 6 weeks ago

Nexalin Technology enters agreements to advance HALO Clarity trial

Apr 22, 2026, 9:35 AM EDT - 6 weeks ago

Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment

2026-04-15T14:21:51.000Z - 7 weeks ago

Nexalin Technology advances FDA Alzheimer’s strategy

Apr 15, 2026, 10:00 AM EDT - 7 weeks ago

Nexalin Advances FDA Alzheimer's Strategy Following Landmark Leadership Meetings in the U.S. and China

Apr 14, 2026, 8:30 AM EDT - 7 weeks ago

Join Nexalin's Exclusive Live Investor Webinar and Q&A Session on April 21

Apr 9, 2026, 7:47 AM EDT - 2 months ago

Nexalin Announces Peer-Reviewed Study Showing the Company's DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents

2026-04-07T13:31:54.000Z - 2 months ago

Nexalin Technology price target lowered to $2 from $4 at Maxim

2026-02-24T13:34:50.000Z - 3 months ago

Nexalin announces continued advancement toward trial evaluating HALO Clarity

2026-02-24T13:29:27.000Z - 3 months ago

Nexalin announces continued advancement toward trial evaluating HALO Clarity

Feb 24, 2026, 8:07 AM EST - 3 months ago

Nexalin Announces Pivotal HALO™ Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market

2026-02-23T13:33:27.000Z - 3 months ago

Nexalin ‘commended’ recent Congressional initiative on neurostim research

Feb 23, 2026, 8:18 AM EST - 3 months ago

Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders

2026-02-05T13:46:39.000Z - 4 months ago

Nexalin Technology launches AI-designed virtual clinic platform NeuroCare

Feb 5, 2026, 8:37 AM EST - 4 months ago

Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer's, Mood Disorders, TBI & PTSD Care

2026-02-02T13:56:38.000Z - 4 months ago

Nexalin Technology highlights research validating neurostimulation technology

Feb 2, 2026, 8:45 AM EST - 4 months ago

Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation

2026-01-14T14:05:14.000Z - 5 months ago

Nexalin Technology announces publication of peer-reviewed study on DIFS

Jan 14, 2026, 9:00 AM EST - 5 months ago

Published Peer-Reviewed Study Demonstrates Nexalin's DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD

2025-12-03T13:05:47.000Z - 6 months ago

Nexalin Technology completes FDA Q-sub meeting for Gen-2 SYNC neurostimulation

Dec 3, 2025, 8:00 AM EST - 6 months ago

Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer's Disease Program

Dec 2, 2025, 8:00 AM EST - 6 months ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on December 4

2025-11-18T14:42:34.000Z - 7 months ago

Nexalin announces results for 15 mA neurostimulation device

Nov 18, 2025, 9:00 AM EST - 7 months ago

Nexalin's 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity

2025-11-13T14:21:40.000Z - 7 months ago

Nexalin Technology appoints Carmi Masha as exclusive distributor in Israel

Nov 13, 2025, 9:15 AM EST - 7 months ago

Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel

2025-11-05T13:40:36.000Z - 7 months ago

Nexalin Technology announces FDA acceptance of Q-Sub for Gen-2 SYNC

Nov 5, 2025, 8:30 AM EST - 7 months ago

Nexalin Technology's Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer's Disease and Dementia

2025-10-30T12:46:01.000Z - 7 months ago

Nexalin Technology announces regulatory approval to sell Gen 2 SYNC

Oct 30, 2025, 8:30 AM EDT - 7 months ago

Nexalin Technology Announces Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS™ Device in Israel

2025-10-21T13:10:34.000Z - 8 months ago

Nexalin announces three studies published on Gen-2 Nexalin DIFS technology

Oct 21, 2025, 9:00 AM EDT - 8 months ago

Nexalin's DIFS™ Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer's and Dementia Across Three Peer-Reviewed Studies

2025-10-13T12:40:42.000Z - 8 months ago

Nexalin Technology appoints Robert Rothstein to Scientific Advisory Board

Oct 13, 2025, 8:30 AM EDT - 8 months ago

Nexalin Technology Expands Scientific Advisory Board with Appointment of Dr. Robert Rothstein to Support Alzheimer's and Traumatic Brain Injury Programs

Oct 10, 2025, 8:00 AM EDT - 8 months ago

Nexalin Technology Announces Attendance at the 2025 Maxim Growth Summit

2025-10-09T12:58:39.000Z - 8 months ago

Why Is Nexalin Technology Stock (NXL) Down 20% Today?

Oct 8, 2025, 8:30 AM EDT - 8 months ago

Nexalin Technology Announces Additional Positive Clinical Results in Alzheimer's Disease with Gen-2 SYNC Neurostimulation Device

Sep 25, 2025, 8:30 AM EDT - 9 months ago

Nexalin Technology Announces Issuance of U.S. Patent Covering HALO™ Clarity Device Featuring DIFS™ Technology

Aug 25, 2025, 9:00 AM EDT - 10 months ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on September 9

Aug 1, 2025, 8:30 AM EDT - 10 months ago

Nexalin Technology Appoints Highly Experienced Financial Leader Justin Van Fleet as CFO to Support Nexalin's Next Phase of Growth and Strategic Initiatives

May 28, 2025, 10:00 AM EDT - 1 year ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on June 3

May 13, 2025, 8:30 AM EDT - 1 year ago

Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer's Program Amid Encouraging Data

May 6, 2025, 2:40 PM EDT - 1 year ago

Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering

May 5, 2025, 8:20 AM EDT - 1 year ago

Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock

May 1, 2025, 10:30 AM EDT - 1 year ago

Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback

Apr 24, 2025, 9:00 AM EDT - 1 year ago

Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia

Apr 23, 2025, 9:15 AM EDT - 1 year ago

Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices

Apr 14, 2025, 12:30 PM EDT - 1 year ago

Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders

Apr 2, 2025, 8:30 AM EDT - 1 year ago

Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial

Mar 26, 2025, 8:30 AM EDT - 1 year ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on April 3

Mar 3, 2025, 8:30 AM EST - 1 year ago

Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders

Feb 28, 2025, 8:30 AM EST - 1 year ago

Nexalin Technology Announces Initiation of Patient Recruitment for UCSD's TBI & PTSD Clinical Study Following IRB Approval

Feb 26, 2025, 8:30 AM EST - 1 year ago

Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board

Feb 18, 2025, 8:30 AM EST - 1 year ago

Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD Treatment

Feb 10, 2025, 9:00 AM EST - 1 year ago

Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition

Feb 3, 2025, 8:30 AM EST - 1 year ago

Nexalin's Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study

Jan 23, 2025, 11:00 AM EST - 1 year ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session, Today, January 23

Dec 23, 2024, 10:00 AM EST - 1 year ago

Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic

Nov 26, 2024, 10:00 AM EST - 1 year ago

New Peer-Reviewed Publication Validates Nexalin's Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market

Nov 1, 2024, 2:00 PM EDT - 1 year ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on November 5th

Nov 1, 2024, 10:34 AM EDT - 1 year ago

Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements

Nov 1, 2024, 9:00 AM EDT - 1 year ago

LOBO EV and Nexalin Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

LOBO

Oct 28, 2024, 8:30 AM EDT - 1 year ago

Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease

MrTicker Jun. 4 at 3:31 PM

$NXL Nexalin Technology Wins US Patent Protecting Neurostimulation Method Through 2042 MT NEWSWIRES 10:26 AM ET 6/4/2026

0 · Reply

focafoca99 Jun. 4 at 3:02 PM

$NXL secures a U.S. patent for dynamic frequency stimulation covering anxiety, depression, and insomnia through 2042.

0 · Reply

MrTicker Jun. 4 at 2:03 PM

0 · Reply

MrTicker Jun. 4 at 2:03 PM

$NXL Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia GLOBENEWSWIRE 9:00 AM ET 6/4/2026

0 · Reply

MaskMaker Jun. 4 at 5:49 AM

$NXL $UNH $VTGN $JNJ

0 · Reply

MaskMaker Jun. 4 at 5:45 AM

$NXL

0 · Reply

MaskMaker Jun. 3 at 8:33 PM

$NXL $VTGN $GRRR

1 · Reply

MaskMaker Jun. 3 at 4:00 PM

$NXL

0 · Reply

MaskMaker Jun. 2 at 6:43 AM

$NXL

0 · Reply

Nousernam3 Jun. 2 at 1:04 AM

$NXL

0 · Reply

MaskMaker Jun. 2 at 12:58 AM

$NXL

0 · Reply

MaskMaker May. 31 at 5:09 AM

$NXL

0 · Reply

Trader1141 May. 29 at 9:51 AM

$PRFX $AKTX $NEXR $MASK Technology stocks on 🔥 Don’t forget about $NXL

0 · Reply

Trader1141 May. 29 at 9:49 AM

$PRFX $NXL 😎💰💰🤑🤑

0 · Reply

MaskMaker May. 29 at 4:25 AM

$NXL

0 · Reply

MaskMaker May. 29 at 12:23 AM

$NXL

0 · Reply

SadyK189 May. 28 at 8:07 PM

Here is my Amazing daily "Stocktwits" report 2/2: $CODX $NXL $ATPC $NCPL $JDZG CODX Price 5.01. My post was "Initially alerted at 2.18. Still looking good on daily chart. Key support at 3.65 - 3.9. Next key level to test 5.8 - 6.15" It made a MASSIVE move to 13.54 NXL Price at 0.46. My post was "Looking good on 4hours chart. Key support at 0.32 - 0.35. Next key level to test 0.55 - 0.59." It hit our desired zone, went till 0.6262 ATPC Price 5.43. My post last night "Good close of 4hours candle. 3.9 - 4.3 is acting as key support zone. Next key level to test 6.35 - 6.75." It made a nice move to 8.50 NCPL Price 1.29. My post was "Initially alerted at 0.77 for next key level of 1.08 - 1.19. Still looking good on daily chart. Key support at 0.85 - 0.93. Next key level to test 1.65 - 1.8" It hit our desired zone, went till 1.86 JDZG Price 3.45. My post was "Looking good on 4hours chart. Key support at 2.4 - 2.7. Next key level to test 3.9 - 4.25." It hit our desired zone, went till 4.50

0 · Reply

SadyK189 May. 28 at 6:25 PM

Mid-Day Update: 2/2 🚀 🎯 Levels respected perfectly: $CODX → called at 2.18 → went till 13.54 (+521%)🔥 $NXL → called at 0.46 → went till 0.6262 (+36%)🚀 $ATPC → called at 5.43 → went till 8.50 (+57%)✅ $NCPL → called at 0.60 → went till 1.73 (+188%)📈 $JDZG → called at 3.45 → went till 4.31 (+25%)🔥 All levels shared earlier (in detailed posts) and reacting cleanly.

0 · Reply

stayenvious May. 28 at 5:38 PM

$YYGH This $MGRX $QTEX $NXL are my picks rn

0 · Reply

nextrated May. 28 at 3:30 PM

$NXL watching if it consolidates towards .55 can hold this on volume spike for an easy 20% gain

0 · Reply

SadyK189 May. 28 at 2:25 PM

$NXL Price at 0.46. My post was "Looking good on 4hours chart. Key support at 0.32 - 0.35. Next key level to test 0.55 - 0.59." It hit our desired zone, at 0.6 now. Next key level to test 0.68 -0.73. It may take sometime though.

0 · Reply

Trader1141 May. 28 at 12:50 PM

$NXL RSI 🔥SP ❄️🤔🤔 cheap…. Why not!?

0 · Reply

Market Cap	10.96M
Revenue (ttm)	300,000.00
Net Income (ttm)	-8.22M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,740.00%
Debt to Equity Ratio	0.00

Volume	824,800
Avg Vol	991,350
Day's Range	N/A - N/A
Shares Out	20.58M
Stochastic %K	65%
Beta	3.80
Analysts	Strong Sell
Price Target	$2.00